Garth Lees-Rolfe - 01 Apr 2024 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKT	Stock Option (right to buy)	Award	$0	+90,000		$0.000000	90,000	01 Apr 2024	Common Stock	90,000	$2.16	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	One-third of the options will vest and become exercisable on April 1, 2025, one-third of the options will vest and become exercisable on April 1, 2026, and one-third of the options will vest and become exercisable on April 1, 2027, in each case subject to continued employment through each such vesting date.